NLS Pharmaceutics AG (NLSP) Stock Price, Financial Report, & Fundamental AnalysisNASDAQ:NLSP
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).
NLS Pharmaceutics AG Fundamental Analysis
Price to Book (PBV) Ratio
Undervalued price-to-book. NLSP stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER)
NLSP equity is higher than it's debt.
Return of Equity
NLSP has GREAT return of equity (257.32%).
Return of Invested Capital
Good ROIC. NLSP is thought to be creating value.
Small market capitalization. Market capitalization is less than 2bn USD
NLSP has never had growing revenue.
Net Income Growth
NLSP has never had growing net income.
NLSP never has positive net income for 2 years.
NLSP has low dividend yield (0%).
Return of Assets
NLSP has low return of asset (-257.38%).
NLSP never has positive revenue for 2 years.
NLS Pharmaceutics AG Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- 0 USD
- 11,860,621 USD
- Net Income
- -11,946,078 USD
- Profit Margin
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -14,975,604 USD
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
Long Term Liabilities
|Dividend Payout Ratio (DPR)||0%|
|Dividend Payout Ratio (DPR)||0%|
|Dividend per Share||0,00 USD|
|Price to Earning (PER)||-1.3x|
|Price to Earning-Growth (PEG)||0x|
|Price to Book Value (PBV)||0x|
|Debt-Equity Ratio (DER)||-150.92%|
|Net Profit Margin (NPM)||0%|
|Return of Assets (ROA)||-257.38%|
|Return of Equity (ROE)||257.32%|
|Return on Capital Employed (ROCE)||282.61%|
|Days of Sales Outstanding (DSO)||0|
|Days of Inventory Outstanding (DIO)||0|
|Days Payable Outstanding (DPO)||0|
|Operating Cycle (OC)||0|
|Cash Conversion Cycle (CCC)||0|
NLS Pharmaceutics AG Executives
- CEO Name
NLS Pharmaceutics AG Profile
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
- Company name
- NLS Pharmaceutics AG
- NASDAQ Capital Market
Alter Postplatz 2